QCG
ADMA icon

Quadrant Capital Group’s ADMA Biologics ADMA Stock Holding History

Quadrant Capital Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69K Sell
187
-526
-74% -$8.3K ﹤0.01% 2531
2025
Q4 		$13K Sell
713
-259
-27% -$4.37K ﹤0.01% 2133
2025
Q3 		$14.3K Sell
972
-15,688
-94% -$269K ﹤0.01% 2058
2025
Q2 		$303K Buy
16,660
+629
+4% +$12.8K 0.01% 1133
2025
Q1 		$318K Buy
16,031
+15,429
+2,563% +$267K 0.01% 1048
2024
Q4 		$10.3K Sell
602
-390
-39% -$7.34K ﹤0.01% 2118
2024
Q3 		$19.8K Buy
+992
New +$15.4K ﹤0.01% 1892
2023
Q4 		– Sell
-867
Closed -$3.1K – 2693
2023
Q3 		$3.1K Hold
867
– – ﹤0.01% 2284
2023
Q2 		$3.2K Hold
867
– – ﹤0.01% 2307
2023
Q1 		$2.87K Buy
+867
New +$3K ﹤0.01% 2357

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Quadrant Capital Group's ADMA Position: Q1 2026 in Review

Quadrant Capital Group reduced its ADMA Biologics (ADMA) stake by 74% in Q1 2026, selling an estimated $8.3K and leaving 187 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #2531.

Quadrant Capital Group first reported a position in ADMA in Q1 2023 and has held it in 10 quarters since. The position peaked at $318K in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Quadrant Capital Group held 187 shares of ADMA Biologics worth $1.69K as of Q1 2026.
  • Quadrant Capital Group sold 526 ADMA Biologics shares in Q1 2026, an estimated $8.3K.
  • ADMA Biologics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2531 holding.
  • Quadrant Capital Group first reported a position in ADMA Biologics in Q1 2023 and has held it in 10 quarters since.
  • Quadrant Capital Group's ADMA Biologics position peaked at $318K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.